100 related articles for article (PubMed ID: 20615919)
1. Impact of diuretic treatment and sodium intake on plasma volume in patients with compensated systolic heart failure.
Bonfils PK; Damgaard M; Taskiran M; Goetze JP; Norsk P; Gadsbøll N
Eur J Heart Fail; 2010 Sep; 12(9):995-1001. PubMed ID: 20615919
[TBL] [Abstract][Full Text] [Related]
2. Medium term effects of different dosage of diuretic, sodium, and fluid administration on neurohormonal and clinical outcome in patients with recently compensated heart failure.
Paterna S; Parrinello G; Cannizzaro S; Fasullo S; Torres D; Sarullo FM; Di Pasquale P
Am J Cardiol; 2009 Jan; 103(1):93-102. PubMed ID: 19101237
[TBL] [Abstract][Full Text] [Related]
3. Association of furosemide dose with clinical status, left ventricular dysfunction, natriuretic peptides, and outcome in clinically stable patients with chronic systolic heart failure.
Dini FL; Guglin M; Simioniuc A; Donati F; Fontanive P; Pieroni A; Orsini E; Caravelli P; Marzilli M
Congest Heart Fail; 2012; 18(2):98-106. PubMed ID: 22432556
[TBL] [Abstract][Full Text] [Related]
4. Altered sodium intake affects plasma concentrations of BNP but not proBNP in healthy individuals and patients with compensated heart failure.
Damgaard M; Goetze JP; Norsk P; Gadsbøll N
Eur Heart J; 2007 Nov; 28(22):2726-31. PubMed ID: 17942579
[TBL] [Abstract][Full Text] [Related]
5. Independent value of echocardiography and N-terminal pro-natriuretic Peptide for the prediction of major outcomes in patients with suspected heart failure.
Lim TK; Hayat SA; Gaze D; Celik E; Collinson P; Senior R
Am J Cardiol; 2007 Sep; 100(5):870-5. PubMed ID: 17719336
[TBL] [Abstract][Full Text] [Related]
6. Plasma matrix metalloproteinase-9 better predicts outcome than N-terminal protype-B natriuretic peptide in patients with systolic heart failure and a high prevalence of coronary artery disease.
Dini FL; Buralli S; Bajraktari G; Elezi S; Duranti E; Metelli MR; Carpi A; Taddei S
Biomed Pharmacother; 2010 May; 64(5):339-42. PubMed ID: 19944559
[TBL] [Abstract][Full Text] [Related]
7. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure.
Cataliotti A; Boerrigter G; Costello-Boerrigter LC; Schirger JA; Tsuruda T; Heublein DM; Chen HH; Malatino LS; Burnett JC
Circulation; 2004 Apr; 109(13):1680-5. PubMed ID: 15023890
[TBL] [Abstract][Full Text] [Related]
8. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study.
Anwaruddin S; Lloyd-Jones DM; Baggish A; Chen A; Krauser D; Tung R; Chae C; Januzzi JL
J Am Coll Cardiol; 2006 Jan; 47(1):91-7. PubMed ID: 16386670
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.
Grewal J; McKelvie RS; Persson H; Tait P; Carlsson J; Swedberg K; Ostergren J; Lonn E
Am J Cardiol; 2008 Sep; 102(6):733-7. PubMed ID: 18773998
[TBL] [Abstract][Full Text] [Related]
10. The benefits of using a heart failure management programme in Swedish primary healthcare.
Agvall B; Alehagen U; Dahlström U
Eur J Heart Fail; 2013 Feb; 15(2):228-36. PubMed ID: 23109650
[TBL] [Abstract][Full Text] [Related]
11. [Comparison study on diagnostic and prognostic value of N-terminal pro-brain natriuretic peptide and atrium natriuretic peptide in chronic congestive heart failure].
Li YJ; Wang L; Chen KY; Chen YL; Cai JR; Zhou LJ
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2005 Sep; 17(9):544-7. PubMed ID: 16146600
[TBL] [Abstract][Full Text] [Related]
12. Lack of decrease in plasma N-terminal pro-brain natriuretic peptide identifies acute heart failure patients with very poor outcome.
Kubler P; Jankowska EA; Majda J; Reczuch K; Banasiak W; Ponikowski P
Int J Cardiol; 2008 Oct; 129(3):373-8. PubMed ID: 18054808
[TBL] [Abstract][Full Text] [Related]
13. Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death.
Moertl D; Berger R; Struck J; Gleiss A; Hammer A; Morgenthaler NG; Bergmann A; Huelsmann M; Pacher R
J Am Coll Cardiol; 2009 May; 53(19):1783-90. PubMed ID: 19422985
[TBL] [Abstract][Full Text] [Related]
14. [Comparison study on diagnostic and prognostic value of N-terminal probrain natriuretic peptide and atrium natriuretic peptide in chronic congestive heart failure].
Dong H; Chen DQ; Wang Y; Li M
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(9):1740-2. PubMed ID: 18819908
[TBL] [Abstract][Full Text] [Related]
15. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.
Licata G; Di Pasquale P; Parrinello G; Cardinale A; Scandurra A; Follone G; Argano C; Tuttolomondo A; Paterna S
Am Heart J; 2003 Mar; 145(3):459-66. PubMed ID: 12660669
[TBL] [Abstract][Full Text] [Related]
16. Comparison of prognostic significance of amino-terminal pro-brain natriuretic Peptide versus blood urea nitrogen for predicting events in patients hospitalized for heart failure.
Shenkman HJ; Zareba W; Bisognano JD
Am J Cardiol; 2007 Apr; 99(8):1143-5. PubMed ID: 17437744
[TBL] [Abstract][Full Text] [Related]
17. NT-proBNP in monitoring treatment of patients with congestive heart failure.
Al-Meslmani BM; Fahoum SK; Shamia MG
Clin Lab; 2007; 53(1-2):35-9. PubMed ID: 17323823
[TBL] [Abstract][Full Text] [Related]
18. Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.
Bhardwaj A; Rehman SU; Mohammed A; Baggish AL; Moore SA; Januzzi JL
Am Heart J; 2010 Apr; 159(4):532-538.e1. PubMed ID: 20362709
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure.
van Kimmenade RR; Pinto YM; Bayes-Genis A; Lainchbury JG; Richards AM; Januzzi JL
Am J Cardiol; 2006 Aug; 98(3):386-90. PubMed ID: 16860029
[TBL] [Abstract][Full Text] [Related]
20. Ruling out heart failure in primary-care: the cost-benefit of pre-screening using NT-proBNP and QRS width.
Goode KM; Clark AL; Cleland JG
Int J Cardiol; 2008 Nov; 130(3):426-37. PubMed ID: 18178273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
